Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David V Gauvin

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
Drug and Alcohol Dependence|October 20, 2022
Letter to the Editor: Cannabidiol is psychoactiveDavid V Gauvin
Journal of Pharmacological and Toxicological Methods|July 1, 2008
A functional observational battery in non-human primates for regulatory-required neurobehavioral assessmentsDavid V Gauvin, Theodore J Baird
Journal of Pharmacological and Toxicological Methods|May 9, 2021
Study design criteria for regulatory-based drug control action: Drug discriminationDavid V Gauvin, Zachary J Zimmermann
Psychopharmacology|November 12, 2018
A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdueDavid V Gauvin, Zachary J Zimmermann
Journal of Pharmacological and Toxicological Methods|March 20, 2019
FOB vs modified Irwin: What are we doing?David V Gauvin, Zachary J Zimmermann
International Journal of Toxicology|December 27, 2023
A Commentary on Fasting of Nonclinical Research AnimalsDavid V Gauvin, Margaret McComb, Ryan Farero
Journal of Psychopharmacology (Oxford, England)|June 20, 2018
Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley ratsZachary J Zimmermann, David V Gauvin, Alan Poling
Regulatory Toxicology and Pharmacology : RTP|November 23, 2018
In further defense of nonclinical abuse liability testing of biologicsDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Journal of Pharmacological and Toxicological Methods|March 20, 2017
Method of data interpretation for the determination of abuse liability in rodent self-administration studies under the FDA guidance documentDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Regulatory Toxicology and Pharmacology : RTP|January 12, 2022
De-risking in Tier I CNS safety assessments is the primary function of study design and technical training of laboratory staff observersDavid V Gauvin, Zachary J Zimmermann, Jill A Dalton
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
Drug and Alcohol Dependence|October 20, 2022
Letter to the Editor: Cannabidiol is psychoactiveDavid V Gauvin
Journal of Pharmacological and Toxicological Methods|July 1, 2008
A functional observational battery in non-human primates for regulatory-required neurobehavioral assessmentsDavid V Gauvin, Theodore J Baird
Journal of Pharmacological and Toxicological Methods|May 9, 2021
Study design criteria for regulatory-based drug control action: Drug discriminationDavid V Gauvin, Zachary J Zimmermann
Psychopharmacology|November 12, 2018
A reply to Henningfield, Fant & Wang (2018): regulatory action to control kratom is long overdueDavid V Gauvin, Zachary J Zimmermann
Journal of Pharmacological and Toxicological Methods|March 20, 2019
FOB vs modified Irwin: What are we doing?David V Gauvin, Zachary J Zimmermann
International Journal of Toxicology|December 27, 2023
A Commentary on Fasting of Nonclinical Research AnimalsDavid V Gauvin, Margaret McComb, Ryan Farero
Journal of Psychopharmacology (Oxford, England)|June 20, 2018
Discriminative stimulus effects of cocaine-levamisole combinations in Sprague-Dawley ratsZachary J Zimmermann, David V Gauvin, Alan Poling
Regulatory Toxicology and Pharmacology : RTP|November 23, 2018
In further defense of nonclinical abuse liability testing of biologicsDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Journal of Pharmacological and Toxicological Methods|March 20, 2017
Method of data interpretation for the determination of abuse liability in rodent self-administration studies under the FDA guidance documentDavid V Gauvin, Zachary J Zimmermann, Theodore J Baird
Regulatory Toxicology and Pharmacology : RTP|January 12, 2022
De-risking in Tier I CNS safety assessments is the primary function of study design and technical training of laboratory staff observersDavid V Gauvin, Zachary J Zimmermann, Jill A Dalton
Pageof 4